Vimizim

Chemical Nameelosulfase alfa
Dosage FormInjection (intravenous; 5 mg/5 mL (1 mg/mL))
Drug ClassEnzymes
SystemMusculoskeletal
CompanyBioMarin
Approval Year2014

Indication

  • Treatment for Mucopolysaccharidosis type IVA (Morquio A syndrome).
Last updated on 7/18/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Vimizim (elosulfase alfa) Prescribing Information.2019BioMarin Pharmaceutical Inc., Novato, CA